Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing Royalty Pharma (Nasdaq: RPRX) agreed to provide $250 million to Zymeworks (Nasdaq: ZYME) via a non‑recourse royalty‑backed note secured by 30% of worldwide tiered royalties on Ziihera until repayment.Repayment ends when Royalty Pharma receives 1.65x the note by Dec 31, 2033, or 1.925x thereafter; Zymeworks retains 70% royalties and all milestone payments up to $1.5 billion potential remaining. Proceeds fund share repurchases, potential acquisitions, and cash runway beyond 2028.

#RPRX Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 Royalty Pharma (Nasdaq: RPRX) will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Investors can obtain conference call details and view the live webcast via the company's Investors page, and a replay will be archived on the site for at least 30 days.

#RPRX Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including

#RPRX Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Royalty Pharma (Nasdaq: RPRX) agreed to provide up to $500 million to accelerate Teva's anti‑IL‑15 antibody, TEV‑'408, including $75 million of R&D co‑funding to support a Phase 2b vitiligo study targeted to start in 2026 and a Royalty Pharma option to provide an additional $425 million to co‑fund a Phase 3 program. TEV‑'408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, and Teva expects to share trial results during 2026.If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of TEV‑'408.

#RPRX Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on

#RPRX Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

www.stocktitan.net/news/RPRX/royalty-pharma...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#VIAV, #ASAN, #SLI, #RPRX, #MLYS

#OptionFlow #OptionsTrading #Trading

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million Royalty Pharma (Nasdaq: RPRX) acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from a third party for up to $315 million.Both are next-generation TKIs for ALK and ROS1 mutation-positive NSCLC. Neladalkib reported positive pivotal results in November 2025 and is in a Phase 3 study in TKI-naïve patients. Zidesamtinib is under U.S. FDA review with an action date of September 18, 2026 and is in Phase 1/2 for TKI-naïve patients.Royalty Pharma acquired a low-single-digit royalty on worldwide net sales, with expected royalty duration through approximately 2041–2042. Existing analyst consensus projects peak sales of about $3.5B for neladalkib and $1.9B for zidesamtinib by 2035.

#RPRX Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement Royalty Pharma (Nasdaq: RPRX) agreed to provide $275 million in synthetic royalty funding to Denali Therapeutics (Nasdaq: DNLI) tied to future net sales of tividenofusp alfa for MPS II (Hunter syndrome).Royalty Pharma will pay $200 million at closing and an additional $75 million upon EMA approval by Dec 31, 2029. In return, Royalty Pharma receives a 9.25% royalty on worldwide net sales, capped at a 3.0x multiple (or 2.5x if reached by Q1 2039). The transaction requires U.S. FDA accelerated approval (PDUFA date Apr 5, 2026).

#RPRX Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences Royalty Pharma (Nasdaq: RPRX) acquired a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences for $310 million. Royalty Pharma purchased Blackstone’s 1% royalty on worldwide net sales covering AMVUTTRA sales beginning October 1, 2025, with the royalty extending through March 2035. AMVUTTRA is an FDA-approved RNAi therapeutic for ATTR amyloidosis; sales were approximately $1 billion in 2024 (+74% year-over-year) and analyst consensus projects sales to exceed $6 billion by 2028. The company said the deal aligns with its return targets across scenarios that include potential competition from Alnylam’s follow-on product nucresiran. Advisors on the transaction were disclosed for both parties.

#RPRX Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes Royalty Pharma (Nasdaq: RPRX) has announced the pricing of $2.0 billion in senior unsecured notes across three tranches: $600 million of 4.450% Notes due 2031, $900 million of 5.200% Notes due 2035, and $500 million of 5.950% Notes due 2055.The notes will be guaranteed by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The offering is expected to close on September 16, 2025. The company plans to use the proceeds for general corporate purposes. Multiple financial institutions, led by BofA Securities, Goldman Sachs, J.P. Morgan, Morgan Stanley, and TD Securities, are serving as joint book-running managers.

#RPRX Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

www.stocktitan.net/news/RPRX/royalty-pharma...

$300M Biotech Deal: Royalty Pharma Backs Promising Autoimmune Drug with Blockbuster Potential Initial $75M payment plus $225M in milestone funding for obexelimab development in IgG4-RD, MS, and lupus. Phase 3 trial results expected year-end 2025. Potential launch in H1 2027.

#RPRX Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million Royalty Pharma (NASDAQ:RPRX) has announced the acquisition of a royalty interest in Amgen's Imdelltra from BeOne Medicines for $885 million upfront, with an additional $65 million option available to BeOne within 12 months. The deal involves approximately 7% royalty on worldwide net sales of Imdelltra, extending through 2038-2041.Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), received FDA accelerated approval in May 2024 for treating extensive-stage small cell lung cancer. The drug achieved $215 million in sales during H1 2025 and is projected to reach $2.8 billion by 2035. The agreement includes royalty sharing with BeOne on annual net sales above $1.5 billion, while BeOne retains China commercial rights.

#RPRX Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million

www.stocktitan.net/news/RPRX/royalty-pharma...

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million BeOne Medicines (Nasdaq: ONC) has entered into a significant royalty purchase agreement with Royalty Pharma for up to $950 million for IMDELLTRA® worldwide sales rights (excluding China). The deal includes an $885 million upfront payment and a potential additional $65 million within 12 months.IMDELLTRA® is a groundbreaking DLL-3 targeting bispecific T-cell engager approved for treating extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after platinum-based chemotherapy. BeOne will retain a portion of royalties on annual sales above $1.5 billion and maintain rights to other assets under its Amgen collaboration, including xaluritamig.

#ONC #RPRX BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

www.stocktitan.net/news/ONC/be-one-medicine...

Royalty Pharma (RPRX) Q2 Receipts Up 20% | The Motley Fool

#RPRX #3ef8fad6-745f-4b9c-a556-ce22e98dbb0c #data-news

Origin | Interest | Match

Royalty Pharma Delivers Record Q2 Growth, Boosts 2025 Outlook After $727M Portfolio Receipts Q2 Portfolio Receipts surge 20% to $727M with strong performance across key products. Company raises full-year guidance amid strategic expansion. See full results.

#RPRX Royalty Pharma Reports Second Quarter 2025 Results

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion ATI Inc. (NYSE: ATI) has been reclassified under the Global Industry Classification Standard (GICS) from Metals and Mining to Aerospace and Defense effective May 1, 2025. This change reflects ATI's strategic transformation into a leading A&D supplier, with approximately 66% of Q1 2025 revenue coming from the aerospace and defense sector.The company has been executing its A&D-focused strategy since 2020, concentrating on producing highly differentiated materials for aerospace and defense customers while exiting lower-value metal products. ATI's materials support all commercial platforms, airframes, engines, and significant national defense programs.

#RPRX Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Completes the Acquisition of Its External Manager Royalty Pharma (RPRX) has completed the acquisition of its external manager, RP Management, LLC, with 99.9% shareholder approval. The internalization marks a significant shift from the company's previous external management model that had been in place since 1996. Under the former structure, Royalty Pharma paid quarterly fees of 6.5% of Portfolio Receipts and 0.25% of security investments value to RP Management.The transaction integrates all RP Management employees into Royalty Pharma. Management team members (excluding CEO Pablo Legorreta) will receive about 50% of transaction equity, vesting through 2033. Legorreta's equity will vest over five years. The company will update its 2025 guidance to reflect this change in Q2 2025 results.

#RPRX Royalty Pharma Completes the Acquisition of Its External Manager

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition Royalty Pharma (NASDAQ: RPRX) has received overwhelming shareholder approval (99.9% of votes) to acquire its external manager. The internalization transaction, valued at approximately $1.1 billion, will be paid primarily through 24.5 million shares of equity (vesting over 5-9 years), $100 million in cash, and assumption of $380 million in Manager debt.The acquisition brings significant benefits including projected cash savings of over $100 million in 2026, growing to over $175 million by 2030, with cumulative savings exceeding $1.6 billion over ten years. The transaction will transform Royalty Pharma from an external management model to an integrated corporate structure, with all Manager employees becoming direct company employees. [ "Significant cash savings: >$100M in 2026, >$175M in 2030, >$1.6B over 10 years", "Strong shareholder support with 99.9% approval", "Enhanced corporate governance and transparency", "Strengthened shareholder alignment through equity-based compensation", "Management retention secured through 5-9 year share vesting period" ]

#RPRX Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Reports First Quarter 2025 Results Royalty Pharma (RPRX) reported strong Q1 2025 financial results with Portfolio Receipts growing 17% to $839 million and Royalty Receipts up 12% to $788 million. The company raised its full-year 2025 guidance, now expecting Portfolio Receipts between $2,975-$3,125 million. Key highlights include: repurchase of 23 million shares for $723 million, a 5% dividend increase, and $101 million in capital deployment. Strong performance was driven by the cystic fibrosis franchise, Trelegy, and Xtandi. The company is on track to acquire its external manager in Q2 2025, expecting to generate over $100 million in cash savings by 2026. The quarter saw positive clinical updates, including FDA and EC approvals for Tremfya in Crohn's disease and ulcerative colitis.

#RPRX Royalty Pharma Reports First Quarter 2025 Results

www.stocktitan.net/news/RPRX/royalty-pharma...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PROP, #EBAY, #RPRX, #EA, #PRVA

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SNAP, #RPRX, #GME, #DKNG, #CVX

#OptionFlow #OptionsTrading #Trading

Massive $250M Deal: Royalty Pharma Backs Revolutionary Lupus Treatment in Late-Stage Trials Royalty Pharma commits $250M to Biogen's litifilimab development, targeting first-in-class lupus treatment with Phase 3 trials underway and potential global impact.

#RPRX Royalty Pharma Announces R&D Funding Collaboration With Biogen

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Reports Q4 and Full Year 2024 Results Royalty Pharma (RPRX) reported strong financial results for Q4 and FY 2024, with Portfolio Receipts reaching $742 million in Q4 and $2,801 million for FY 2024. The company achieved 12% growth in Royalty Receipts in Q4 and 13% for FY 2024, driven by strong performance from products including Evrysdi, CF franchise, Trelegy, and Tremfya.Key highlights include $2.8 billion in capital deployment in 2024, with royalties acquired on eight new therapies. The company provided 2025 guidance projecting Portfolio Receipts between $2,900-$3,050 million, representing 4-9% growth. Net cash from operations was $743 million in Q4 and $2,769 million for FY 2024.In January 2025, RPRX announced a new $3 billion share repurchase program, with plans to repurchase $2 billion in 2025. The company also announced the acquisition of its external manager, expected to generate over $100 million in cash savings by 2026.

#RPRX Royalty Pharma Reports Q4 and Full Year 2024 Results

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Cashes Out MorphoSys Investment for Massive 77% Profit - Smart Money Move? Royalty Pharma monetizes MorphoSys bonds for $511M upfront cash, achieving $530M total return on $300M investment. Proceeds targeted for share buybacks and new royalty acquisitions.

#RPRX Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

www.stocktitan.net/news/RPRX/royalty-pharma...

Royalty Pharma Earnings: Strategic Timing Ahead of Market Open Reveals Key Financial Insights Royalty Pharma announces Q4 and full-year 2024 financial results presentation scheduled for February 11, featuring management conference call and webcast at 8:30 AM ET.

#RPRX Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

www.stocktitan.net/news/RPRX/royalty-pharma...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BCE, #SAND, #RPRX, #BMBL, #PLX

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #BCE 4.2x
2. #SAND 3.3x
3. #RPRX 3.2x
4. #BMBL 3.0x
5. #PLX 2.7x

#OptionFlow #OptionsTrading #Trading

Breaking News: ( NASDAQ: #RPRX ) Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Breaking News: ( NASDAQ: #RPRX ) Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma Hits Record $2.8B in Deals, Projects $1.2B Peak Pipeline Royalties Royalty Pharma achieves 13% YoY growth with $2.8B portfolio receipts, sets synthetic royalty record of $925M, and expects multiple product launches in 2025 with strong pipeline potential.

#RPRX Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/RPRX/royalty-pharma...